PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC

2025-09-08
(Press-News.org) (Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) ) — A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).

The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

In hypofractionated radiotherapy for lung cancer treatment, clinicians deliver fewer radiation treatments (fractions) at higher doses per session compared to standard radiotherapy schedules.

The study, conducted across 16 hospitals in China, randomized 530 patients to receive either HypoRT (45 Gy in 15 daily fractions over 3 weeks) or ConvRT (60 Gy in 30 daily fractions over 6 weeks), both given with concurrent cisplatin/carboplatin-etoposide chemotherapy. At a median follow-up of 43.4 months, median overall survival (OS) was 40.2 months in the HypoRT arm and 47.9 months in the ConvRT arm (HR=1.04; 95% CI, 0.81–1.33). Progression-free survival was also similar between the groups.

Patients receiving HypoRT experienced significantly fewer severe treatment-related adverse events including lower rates of hematologic toxicity, lymphopenia, and radiation pneumonitis. Acute grade ≥3 adverse events occurred in 48.7% of HypoRT patients compared to 67.7% in the ConvRT group.

“Our findings suggest that hypofractionated radiotherapy can provide a shorter, more convenient treatment course with fewer side effects while maintaining comparable survival outcomes to conventional radiotherapy,” said Nan Bi, MD, The National Cancer Center of China/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing. “This approach could be an important option for patients, especially in settings where reducing treatment time and toxicity is a priority.”

The investigators note that further research is warranted to explore HypoRT in combination with immunotherapy given its potential immune-sparing benefits.

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

END


ELSE PRESS RELEASES FROM THIS DATE:

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  Older individuals between the ages of 75 and 80 who are eligible for lung surgery may achieve survival outcomes comparable to younger patients following lung cancer screening, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Despite half of lung cancers being diagnosed in people aged 75 or older, randomized evidence on screening outcomes in this age group is limited. Most national lung cancer screening programs, including the UK’s, stop at age 74. The U.S. Preventive ...

Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  – Patients who underwent video-assisted thoracoscopic surgery (VATS) compared to open lobectomy had a significantly improved overall survival rate, according to a meta-analysis presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Video-assisted thoracoscopic surgery (VATS) is currently the most common approach to perform pulmonary lobectomy in early-stage lung cancer. Advantages include reduced pain, fewer complications, faster recovery and improved quality-of-life. The adoption of VATS lobectomy ...

NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  – Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile. Despite complete surgical resection (R0), early-stage NSCLC carries a substantial risk of recurrence and remains a leading cause of cancer-related ...

EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  — Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival compared to consolidation durvalumab alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Consolidation durvalumab improves survival ...

Training to improve memory

2025-09-08
  In Europe, almost one in 10 people over 70 suffers from dementia, and this figure could even triple by 2050 due to rising life expectancy. Over time, those affected lose everything that makes them who they are, including their memory and their ability to go about their everyday lives. Many also suffer from physical deterioration. In an advanced stage of the disorder, dementia patients generally require comprehensive care. Now, the first drugs have emerged that can slightly slow down disease progression in the early stages of Alzheimer’s – ...

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

2025-09-08
New research indicates that many patients who undergo surgery with the intent to cure early-stage cancer continue or start opioid prescriptions in the year following surgery. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. Pain management is essential during cancer care, but prescription opioid practices associated with cancer treatment may lead to unsafe long-term opioid use and adverse outcomes such as opioid use disorder and opioid overdose. To assess the ...

Black youth, especially Black girls, use mental health services less than their White peers

2025-09-08
Black adolescents with mental distress are less likely to use mental health services than their White peers, and Black girls are the least likely to access care, according to new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241733. “Adolescence is a crucial developmental stage and a critical period for onset of mental health problems,” writes Mercedes Sobers, a PhD candidate in epidemiology at the Dalla Lana School of Public Health, University of Toronto and research coordinator at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, ...

Canada must protect youth from sports betting advertising

2025-09-08
Canada must enact strong, effective legislation to protect youth from gambling advertising. Minors are suffering harms from problem gambling despite age restrictions, argue authors in an editorial in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251227 . Since 2021, ads for sports betting have saturated sports broadcasts, constantly viewed by children. Gambling is normalized as a natural part of spectatorship at a young age. Even before single-game sports betting was legalized, a 2019 survey of Canadian students in grades 7–12 found about 4% of students ...

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

2025-09-07
First-in-Human Trial Shows Promising Results for DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer (Barcelona, Spain Sunday, September 7, 2025 at 4:45 PM CEST / UTC +2) — A first-in-human Phase 1 study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC).  The results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). According to the International Agency for Research on Cancer, ...

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

2025-09-07
(Barcelona, Spain. September 7, 2025 at 4:45 PM CEST / UTC +2 )--Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, according to data presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. New data from the Phase 2 IDeate-Lung01 trial in 137 patients who had received ≥1 prior line of platinum-based chemotherapy showed a confirmed objective response rate (ORR) of ...

LAST 30 PRESS RELEASES:

Flavanols in cocoa can protect blood vessel function following uninterrupted sitting - study

$100 Million gift will advance UCSF’s dementia research and care

The 4th Japan-India Universities Forum on 15 November

Arctic town Kiruna is colder after the move

Mayo Clinic study finds majority of midlife women with menopause symptoms do not seek care

Underwater robot ‘Lassie’ discovers remarkable icefish nests during search for Shackleton’s lost ship off Antarctica

Wearable robots you can wear like clothes: automatic weaving of “fabric muscle” brings commercialization closer

Researcher improves century-old equation to predict movement of dangerous air pollutants.

Heatwaves linked to rise in sleep apnoea cases in Europe

Down‑top strategy engineered large‑scale fluorographene/PBO nanofibers composite papers with excellent wave‑transparent performance and thermal conductivity

The Lancet: Climate change inaction being paid for in millions of lives every year

New insights reveal how coral gets a grip

Home treatment with IV antibiotics could relieve NHS pressure

AI ECG better detects severe heart attacks in emergency setting

Straw-based biochar and smart irrigation help maize thrive with less water and fertilizer

‘Broken’ genes a common factor in marsupial fur colour

Turning waste into clean water: Magnetic carbon materials remove toxic pollutants from wastewater

World Health Organization’s priorities shaped by its reliance on grants from donor organisations such as the Gates Foundation

One in ten people without coeliac disease or wheat allergy report sensitivity to gluten or wheat

How can (A)I help you?

Study finds new system can cut patient waiting times for discharge

Allison Institute’s third annual scientific symposium highlighted by panel discussion with five Nobel laureates

SETI Institute accelerates the search for life beyond earth with NVIDIA IGX Thor

Wetlands efficiently remove nitrogen pollution from surface water, leading to cost savings for municipalities

Dr. Loren Miller presents oral late breaker at IDWeek 2025 of a first-of-its-kind clinical trial that shows efficacy of bacteriophage therapy for Staphylococcus aureus bacteremia

Dirty water boosts prospects for clean hydrogen

New multisociety guidance strengthens infection prevention and control in nursing homes

More scientific analysis needed on impacts of industrial decarbonization

New research uncovers how bad bacteria know where to cluster and cause infection

As ochre sea star ‘baby boomers’ grow up, species showing signs of recovery

[Press-News.org] Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC